Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Metro International Biotech, LLC
Study ID
NCT06882096
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Adults

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Nicotinamide Mononucleotide (NMN) — DRUG
    Nicotinamide Mononucleotide (NMN)
  • Nicotinamide (NAM) — DRUG
    Nicotinamide (NAM)

Study Details

We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues. Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days. Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle. Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells. A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people. Possible benefits and risks: Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge. NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising. Researchers will monitor participants closely for any side effects throughout the study.

Key Dates

Start date
Apr 28, 2025
Status verified
May 2025
Primary completion
Dec 31, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
32 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: NMN- Nicotinamide Mononucleotide
    This arm will include 16 participants (8 young and 8 older adults) who will receive NMN once daily for 14 consecutive days.
  • Active Comparator: NAM- Nicotinamide
    This arm will include 16 participants (8 young and 8 older adults) who will receive NAM once daily for 14 consecutive days.

Primary Outcome Measure

Labelled NAD+ in Peripheral Blood [ Time Frame: During the Study Intervention Period Day 1 through Day 14 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02215
Nancy K Latham, PhD
[email protected]
6179999195
Mohan Sonu Chandra, MBBS
[email protected]
6175259154
Shalender Bhasin, MB,BS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MA

Related Studies